Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A conservative, evidence-first look at where mesenchymal stem cell (MSC) therapy stands for Crohn's disease. The strongest data — including the Lancet ADMIRE-CD trial and a European-approved cell product — is for COMPLEX PERIANAL FISTULAS. For luminal Crohn's the literature is promising but still investigational. At Regeneris Therapy in Cancún, México we frame any regenerative protocol as an ADJUNCT to your gastroenterologist's care, never a replacement for biologics, immunomodulators, or surgery.
Mesenchymal stem cell (MSC) therapy has the strongest evidence in Crohn's disease for complex perianal fistulas — local injection of allogeneic adipose-derived MSCs (Cx601 / darvadstrocel) achieved 50% combined remission versus 34% with placebo at 24 weeks in the Lancet ADMIRE-CD trial. For luminal Crohn's the data are more limited and the indication remains investigational. Regeneris Therapy in Cancún, México evaluates candidates conservatively, coordinates with your gastroenterologist, and publishes no prices online — every protocol begins with a free medical evaluation and a personalized written quote.
What this condition is
Crohn's disease is a chronic, relapsing inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract — most often the terminal ileum and proximal colon — with skip lesions, transmural inflammation, and a tendency toward stricturing or penetrating complications including fistulas, abscesses, and obstruction. Symptoms commonly include abdominal pain, diarrhea (sometimes bloody), weight loss, fatigue, and extra-intestinal manifestations such as arthropathy, skin lesions, or eye inflammation. Standard care is structured by a gastroenterologist and may include 5-aminosalicylates, corticosteroids for flares, immunomodulators (azathioprine, methotrexate), biologic agents (anti-TNF such as infliximab and adalimumab, anti-integrin vedolizumab, anti-IL-12/23 ustekinumab, anti-IL-23 risankizumab), small-molecule JAK inhibitors, nutritional optimization, and — for complications — surgical resection or fistula procedures.
Despite an expanding therapeutic toolkit, a meaningful subset of patients fail to achieve durable remission, experience loss of response over time, or develop complex perianal fistulas that remain difficult to close. It is in those gaps — and only in conversation with the treating specialist — that adjunctive regenerative options are sometimes considered. This page describes how Regeneris Therapy in Cancún, México reasons about that possibility honestly.
What the research shows
"Regenerative therapy for Crohn's" is not one evidence category. The strongest data sit at one specific use — complex perianal fistulas — while luminal use is at a different and earlier stage. An honest comparison reports that gradient rather than implying every application is equally established.
The ADMIRE-CD trial randomized 212 adults with Crohn's disease and treatment-refractory complex perianal fistulas to a single local injection of allogeneic adipose-derived MSCs (Cx601 / darvadstrocel) versus placebo. At 24 weeks, 50% of the MSC group achieved combined remission (clinical closure of all treated external openings plus absence of collections >2 cm on masked central MRI) versus 34% with placebo (p=0.024). On the strength of this trial Cx601 became the first allogeneic stem cell product approved by the European Medicines Agency for this indication.
A randomized controlled trial of 82 adults with steroid-dependent Crohn's compared four weekly intravenous infusions of umbilical-cord-derived MSCs to control. The MSC group showed greater reductions in Crohn's Disease Activity Index (CDAI), Harvey-Bradshaw Index, and corticosteroid requirement over 12 months, with mild adverse events (transient fever in four patients) and no serious safety concerns. The authors framed luminal MSC use as a supplementary therapy that warrants larger confirmatory trials — not as established care.
Who is — and isn't — a candidate
MSC therapy for Crohn's disease is not for everyone, and many people who reach out are not appropriate candidates. We say so when that is the case. Final candidacy is always confirmed in a physician evaluation, never assumed from a symptom alone.
Regulation & location
COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is Mexico's federal health authority — the regulatory counterpart of the U.S. FDA. It supervises the laboratories that process cellular products, the clinics that administer them, and the medical advertising that surrounds them. Regeneris Therapy operates in Cancún, Quintana Roo, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053. Our cellular products are sourced from a certified Mexican laboratory chain, with documented donor screening, characterization, viability testing, and cold-chain handling.
Why Cancún, México specifically matters for a Crohn's evaluation: the city pairs direct international flights from major U.S. and Canadian hubs with a clinic culture used to coordinating with foreign specialists, English-speaking medical staff, and a recovery setting that is not by accident — controlled travel, low logistical friction, and predictable follow-up are part of the medical decision, not separate from it. Regulation lives upstream of all of that: nothing about a sunny destination changes the standard we apply to your case.
How we evaluate
Crohn's disease is not a single phenotype, so we do not run a single protocol. The flow below describes how a Regeneris physician in Cancún, México reasons about a case from first contact to a documented plan. No prices appear on this page or in the evaluation itself — pricing follows the personalized written quote after your free medical evaluation.
Send recent gastroenterology notes, colonoscopy / endoscopy reports, pelvic MRI (if perianal fistulas are the focus), current and prior medication list, labs (CBC, CRP, calprotectin where available), and imaging. We ask for permission to coordinate with your treating specialist whenever possible — not optional in our model, but a default.
Realistic expectations
Crohn's disease is a chronic relapsing condition. Every honest clinician — gastroenterologist or regenerative — operates inside that fact. Below are the disclaimers we want you to read before you ever sit down with us.
MSC therapy is not a cure for Crohn's disease. The strongest published outcome — combined remission in perianal fistulas — is exactly that: a clinically meaningful improvement over placebo at a defined time point, in a defined complication. It is not a guarantee for your case and not an end-state for the disease.
Anything we offer is positioned as ADJUNCT to standard gastroenterology care. We do not advise stopping biologics, immunomodulators, or a surgical plan in pursuit of a regenerative outcome. That is the line we will not cross.
Clinical trial averages do not predict your outcome. Some patients respond, some respond partially, some do not respond. We say so up front, and our written plan reflects it.
For luminal Crohn's, MSC therapy remains investigational. We discuss what the data do and do not show, and we do not market it as approved or established care for luminal disease — because it is not.
FAQ
The questions patients ask us most when weighing stem cell therapy for Crohn's disease at Regeneris in Cancún, México.
No. Mesenchymal stem cell (MSC) therapy is not a cure for Crohn's disease. The strongest published benefit — combined remission in complex perianal fistulas in the Phase 3 ADMIRE-CD trial — is a clinically meaningful improvement at 24 weeks in that specific complication, not a cure for the disease. Crohn's is a chronic relapsing condition, and any honest clinician (regenerative or otherwise) frames outcomes in that context. At Regeneris in Cancún, México we present MSC therapy as a potential adjunct to standard gastroenterology care, never as a replacement.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for Crohn's disease is investigational for many uses; the strongest published evidence is for complex perianal fistulas (Cx601 / darvadstrocel, EU-approved on the basis of the Lancet ADMIRE-CD trial), and luminal use remains investigational. Outcomes vary by patient, disease phenotype, prior therapy, and protocol. Decisions about your Crohn's care — including any regenerative adjunct — require an individualized evaluation with a licensed physician and coordination with your treating gastroenterologist. Regeneris Therapy operates in Cancún, México under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053.
Book a free 15-min call with our team.
Send your gastroenterology records, recent imaging (pelvic MRI for fistulas), and current medication list. A Regeneris physician in Cancún, México will review your case and tell you honestly whether MSC therapy is reasonable — with a personalized written quote after your free medical evaluation.
A 2021 systematic review and meta-analysis pooled 46 studies (28 animal works and 18 human trials, n=360 patients) and reported reductions in CDAI, endoscopic severity scores, and improvements in IBD quality-of-life measures after MSC transplantation, with remission rates maintained 3–24 months. The authors concluded that stem cell transplantation is a valuable supplementary therapy for Crohn's disease — explicitly positioning it as an adjunct, not a primary substitute for established care.
A meta-analysis of seven randomized controlled trials of MSC therapy in perianal fistulizing Crohn's disease reported higher healing rates with MSC injection than control across both short- and long-term follow-up, with no significant excess of MSC-attributable adverse events. The authors concluded MSC therapy offers favorable long-term efficacy and safety for this specific complication.
The field's own founder reframed MSCs as "medicinal signaling cells," arguing that benefit comes chiefly from secreted paracrine factors (exosomes, growth factors, cytokines) rather than engraftment and tissue replacement. That mechanism — broad immunomodulation and dampening of chronic inflammation — is the conceptual basis for testing MSCs in inflammatory bowel disease.
Practical takeaway: ask not "is it regenerative?" but "what is the evidence for THIS specific use, in a patient like me?" That question — and the honest answer — is exactly what a medical evaluation is for.
Telemedicine first when distance is involved, with an in-person consultation on application day in Cancún, México. The evaluation discusses goals honestly, identifies the strongest evidence-matched use (e.g. local injection for fistulas, or adjunctive systemic protocol for selected luminal cases), and — equally important — when the right answer is to defer.
If a regenerative course is reasonable, you receive a written plan and a personalized written quote — what is included, what is not, the schedule, the follow-up cadence, and the honest disclaimers. No upselling, no price published online, no obligation to proceed. If the answer is no, that is documented too.
Cellular product released against documented release criteria from a COFEPRIS-certified laboratory. Local injection or IV administration as per the plan, monitored on the day. Structured follow-up (clinical assessment, labs, and — for fistulas — imaging) is scheduled before you fly home, with continued coordination with your gastroenterology team.
The strongest evidence is for complex perianal fistulas. In the Phase 3 ADMIRE-CD trial (Panés et al., Lancet 2016), 212 adults with Crohn's-related complex perianal fistulas refractory to conventional therapy were randomized to a single local injection of allogeneic adipose-derived MSCs (Cx601 / darvadstrocel) or placebo. At 24 weeks, 50% of the MSC group achieved combined remission versus 34% with placebo (p=0.024). On the strength of that trial, Cx601 became the first allogeneic stem cell product approved by the European Medicines Agency for that indication. Evidence for luminal Crohn's is less mature.
For luminal Crohn's, MSC therapy is investigational. A randomized controlled trial of umbilical-cord MSCs in steroid-dependent Crohn's (Zhang et al., Gut and Liver 2018) reported reductions in Crohn's Disease Activity Index and corticosteroid requirement over 12 months, and a 2021 systematic review and meta-analysis (Yu et al., Stem Cell Res Ther) framed MSC therapy as a valuable supplementary therapy. None of those data establish luminal MSC use as approved or standard care. At Regeneris in Cancún, México we discuss it honestly as adjunctive and investigational — never as a substitute for biologics, immunomodulators, or surgery.
Yes — coordination is our default, not optional. Before any application day in Cancún, México we ask for permission to communicate with your treating gastroenterologist, share the proposed plan, and align on follow-up. We are not interested in being a parallel track that competes with your specialist's care. If your gastroenterologist has reservations, we want to hear them and document them. If a regenerative course is not reasonable for your case, that is documented too, and you receive no quote.
It depends on the indication. For complex perianal fistulas the evidence base (ADMIRE-CD) supports a single local injection of allogeneic adipose-derived MSCs into the fistula tracts under appropriate guidance — that is the regimen with the strongest data. For adjunctive use in selected luminal cases the published RCT (Zhang et al.) used four weekly intravenous infusions of umbilical-cord MSCs. The route, dose, and schedule for your case are determined in your medical evaluation with a Regeneris physician in Cancún, México, documented in your written plan, and coordinated with your gastroenterologist.
No — and you should not stop on your own under any circumstance. Decisions about pausing, continuing, or adjusting biologics or other Crohn's medications belong to your treating gastroenterologist. In our coordination with your specialist we discuss timing relative to your infusion schedule, but the prescribing decisions remain with the physician who manages your Crohn's. Anyone who tells you to stop your biologic in order to receive a regenerative therapy is not following appropriate practice — and that is not how we work in Cancún, México.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How COFEPRIS regulation, certified laboratories, donor screening, and physician oversight protect patients receiving regenerative care in México.